Quick answer
What is AOD-9604 and how is it built? AOD-9604 is a synthetic 16-residue peptide made from the C-terminal end of human growth hormone; the product page labels it hGH (176-191). The sequence on the V8 product page is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, molecular formula C78H123N23O23S2, with a disulfide loop between its two cysteines. The design idea was to isolate the part of growth hormone associated with lipolysis in cell and rodent models and discard the rest. Published mouse studies reported lipolytic and fat-oxidation readouts and increased β3-adrenergic receptor expression, while the fragment lacks most of the parent protein. This article explains the structure, the logic of the fragment approach and what the preclinical record does and does not show. For laboratory research use only.
Most explanations of AOD-9604 begin with what it is said to do. This one begins with what it is: a deliberately truncated piece of a larger protein, with one small chemical modification and one ring. Understanding that construction explains why the molecule is studied the way it is, why its handling requirements differ from linear peptides and where the published evidence stops. All content here describes in vitro and preclinical laboratory work. The material discussed is for laboratory research use only and not for human consumption.
From growth hormone to a fragment
Human growth hormone is a 191-residue protein with a four-helix bundle fold. It acts on many tissues through the growth hormone receptor, and several of its effects are indirect, mediated by IGF-1 produced in the liver. Early work on pituitary extracts and later on recombinant protein showed that the metabolic actions of growth hormone could be partly separated from its growth-promoting actions, and that the C-terminal region was a candidate for the metabolic portion. That observation led to short synthetic peptides covering the end of the sequence.
AOD-9604 is the best-known of them. It corresponds to the C-terminal stretch of the parent protein that contains the Cys182–Cys189 disulfide, and the product page labels the 16-mer hGH (176-191). Literature descriptions often write it as the 177–191 fragment with a tyrosine at the N-terminus; a terminal tyrosine is a common feature of peptides because its aromatic side chain absorbs near 280 nm, which helps with quantitation and labeling. The same product page lists the compound as the C-terminal fragment of human growth hormone, a lyophilized powder at ≥98% HPLC purity in a 5 mg vial.
The relationship to the longer fragment is covered in the AOD-9604 vs hGH fragment 176-191 comparison; the broader compound background is in the AOD-9604 research overview.
| Feature | Parent hGH | AOD-9604 |
|---|---|---|
| Length | 191 residues | 16 residues (C-terminal segment) |
| Fold | Four-helix bundle | Short disulfide-bridged loop with flexible ends |
| Receptor binding | Growth hormone receptor dimer | Not reported to act through the receptor the way the intact protein does |
| Size and complexity | Many domains and contacts | A single short segment |
| Analytical handle | Tryptophan and tyrosine | Single N-terminal tyrosine |
| Chemical liabilities | Many | Disulfide, one methionine-free sequence, no tryptophan |
Reading the sequence
The disulfide loop
Two cysteines, at positions 7 and 14 of the 16-mer, form an intramolecular disulfide. The loop closes a ring of eight residues and holds the C-terminal Gly-Phe tail outside it. Cyclization restricts the conformations the peptide can adopt, which is generally associated with greater resistance to proteases than a linear equivalent. It also introduces the most important handling rule for the molecule: reducing agents such as DTT, TCEP and β-mercaptoethanol open the ring and change the compound under study. Oxidation chemistry of cysteine and methionine side chains is reviewed in general terms by Li and colleagues (1995).
Charged and polar residues
Two arginines and one glutamic acid give a net positive charge near neutral pH. That combination is typical of peptides that dissolve readily in water but adsorb to glass and some plastics, an effect described for peptides in general by Goebel-Stengel and colleagues (2011). It is most noticeable at low concentrations.
The C-terminal phenylalanine
The free-acid C-terminus ends with Gly-Phe. A hydrophobic terminal residue adds some surface affinity, which partly offsets the hydrophilic character of the rest of the sequence. In reverse-phase HPLC the compound elutes as a moderately retained peak; purity values depend on gradient and column and should be read together with the method on the certificate. See understanding HPLC purity and AOD-9604 purity testing.
What the published preclinical record reports
The principal primary reports come from an Australian group working in obese mouse models. Two features of those studies are worth stating plainly, because secondary sources often blur them.
- Species and model. Genetically obese mice and wild-type controls, with comparison to full-length human growth hormone, and a β3-adrenergic receptor knock-out line used to ask about mechanism.
- Route and duration. Intraperitoneal administration over fourteen days in the Endocrinology paper by Heffernan and colleagues (2001), and chronic administration in the companion report in the International Journal of Obesity (2001).
- Readouts. Body fat, lipolytic sensitivity of adipose tissue, fat oxidation and energy expenditure, and β3-AR RNA levels.
- Mechanistic finding. Both growth hormone and the fragment raised β3-AR expression in obese mice toward the level seen in lean mice, but long-term effects were absent in β3-AR knock-out animals, while an acute fat-oxidation effect persisted. The authors concluded that the lipolytic action is not mediated directly through β3-AR.
| Question | What the cited mouse studies address | What they do not address |
|---|---|---|
| Is the fragment active without the full protein? | Yes, lipolytic and fat-oxidation readouts were reported in obese mice | Whether the effect holds across species, strains or diets |
| Does it behave like hGH? | Compared against hGH in the same obese-mouse experiments | Endocrine readouts in other species or systems |
| Is the β3-adrenergic receptor the direct target? | Expression rises, but chronic effects require it and acute ones do not | The actual receptor or binding partner, which remains unresolved |
| How does it compare to related fragments? | Compared in part against hGH itself | Systematic head-to-head work against other fragments in a single design |
The honest summary is that the fragment has a distinctive and reproducible profile in a small number of rodent experiments from closely related groups, and that the molecular mechanism has not been settled. Anyone planning cell-based work should read both primary reports in full and regard the mouse findings as a rationale for choosing readouts rather than as an expected result.
Designing in vitro work with a fragment peptide
Because the receptor target is not firmly established, the choice of assay system is the main design decision.
- Adipocyte models. Differentiated 3T3-L1 cells or primary adipocytes are the usual systems for glycerol and free fatty acid release, with a β-adrenergic agonist as a positive control and an antagonist to probe dependence.
- Parent-protein control. Include intact growth hormone where the aim is to compare fragment and parent, and measure IGF-1 or downstream STAT5 signaling to confirm that the two behave differently in the system used.
- Scrambled or truncated controls. A scrambled sequence of the same composition, or a fragment lacking the cysteines, separates sequence-specific effects from non-specific peptide effects.
- Reduced-form control. Because the disulfide shapes the molecule, a deliberately reduced and alkylated sample shows how much of any signal depends on the ring.
- Vehicle matching. Match diluent, preservative and pH across arms.
Related reading on companion molecules that act on the same axis from the other direction: tesamorelin vs CJC-1295 and growth hormone secretagogues vs hGH.
Handling the material
The AOD-9604 product page lists lyophilized powder in a sealed clear glass research vial and the storage statement: refrigerate at 2–8 °C, −20 °C for long-term, protected from heat, moisture and light. Lyophilization chemistry and its consequences for stability are discussed by Wang (2000) and, for solution-state degradation, by Manning and colleagues (2010). Forced-degradation work, summarized by Hawe and colleagues (2012), shows that temperature, light and agitation are the stresses that matter most for short peptides in solution.
| Step | Practice | Reason tied to this molecule |
|---|---|---|
| Equilibrate | Let the sealed vial reach room temperature before opening | Avoids condensation on a hygroscopic cake |
| Add diluent | Run it slowly down the glass wall | Limits foaming of an amphiphilic C-terminus |
| Mix | Swirl; do not vortex | Shear and air interfaces stress peptides generally |
| Buffer choice | No reducing agents | Keeps the Cys–Cys ring intact |
| Aliquot | Single-use portions, thawed once | Repeated freeze–thaw concentrates solutes and creates ice interfaces |
| Labware | Low-binding tubes and tips | Cationic peptides adsorb to glass and polypropylene |
Concentration is arithmetic: vial mass divided by diluent volume. The reconstitution calculator performs the calculation and its guide explains the inputs. General procedure is in how to reconstitute a lyophilized peptide, and how long reconstituted peptides last covers shelf-life expectations. For sourcing context see where to buy AOD-9604 and AOD-9604 explained; for certificate fields, the COA library and how to read a COA.
Limits of what can be concluded
Three limits apply to any statement about this compound. First, the primary mouse data come from a small number of reports, and replication by independent groups is thin. Second, rodent adipose biology differs from that of other species, so transfer of any finding is an open question, not a default. Third, a short peptide with no confirmed receptor cannot be assumed to behave like its parent protein in a new assay system; the controls described above are how that assumption is tested. The material is supplied for laboratory research use only, and nothing in this article is a recommendation for use in people or animals. Other materials are listed in the shop.
Frequently asked questions
What is AOD-9604?
A synthetic 16-residue peptide derived from the C-terminal portion of human growth hormone, labeled hGH (176-191) on the product page. It contains a disulfide bond between two cysteines.
What is the sequence and formula?
The product page lists Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe and the molecular formula C78H123N23O23S2.
Why does the sequence begin with tyrosine?
Literature descriptions often note an N-terminal tyrosine on the fragment. A terminal tyrosine adds an aromatic side chain that absorbs near 280 nm, which helps with quantitation and labeling.
What did the published mouse studies measure?
Lipolytic sensitivity, fat oxidation, energy expenditure, body fat and β3-adrenergic receptor RNA in obese and knock-out mice, after intraperitoneal administration, compared with full-length growth hormone.
Does the fragment behave like intact growth hormone?
In the cited obese-mouse experiments the two were tested side by side and both raised β3-AR expression and lipolytic readouts. Whether that carries over to another system has to be tested there, including growth hormone-receptor readouts.
Is the β3-adrenergic receptor its direct target?
Not according to the authors of the 2001 Endocrinology paper, who found that expression rose but that the acute fat-oxidation effect persisted in knock-out mice. The direct target is unresolved.
Why must reducing agents be avoided?
DTT, TCEP and β-mercaptoethanol break the disulfide bond that closes the ring, which changes the molecule being studied.
How is it stored?
The product page states 2–8 °C, −20 °C for long-term storage, with protection from heat, moisture and light.
Which controls help interpret a cell-based experiment?
A vehicle arm, intact growth hormone, a scrambled sequence, a reduced and alkylated version and a positive control for the readout, such as a β-adrenergic agonist in adipocyte assays.
Is AOD-9604 for use in people or animals?
No. The product is supplied for laboratory research use only and is not for human or animal consumption.
Related reading: AOD-9604 Amino Acid Sequence and Chemical Structure, AOD-9604 Compatibility and Combination Study Design, AOD-9604 vs Retatrutide: Fragment or Triple Agonist?.
References
- Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. doi:10.1210/endo.142.12.8522
- Heffernan M, Summers RJ, Thorburn A, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic exposure to human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449. doi:10.1038/sj.ijo.0801740
- Li S, Schöneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng. 1995;48(5):490-500. doi:10.1002/bit.260480511
- Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. 2000;203(1-2):1-60. doi:10.1016/S0378-5173(00)00423-3
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
- Hawe A, Wiggenhorn M, van de Weert M, Garbe JHO, Mahler HC, Jiskoot W. Forced degradation of therapeutic proteins. J Pharm Sci. 2012;101(3):895-913. doi:10.1002/jps.22812
- Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
- Bray BL. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat Rev Drug Discov. 2003;2(7):587-593. doi:10.1038/nrd1133
